Abstract 3211
Background
PD-(L)1 inhibitors have been shown to be effective in patients with metastatic urothelial cancer (UC) who are ineligible to receive cisplatin-based chemotherapy, with the PD-L1 inhibitor atezolizumab being FDA-approved. Dysregulation of fibroblast growth factor receptors (FGFR) has been shown to play a role in UC development and progression, and FGFR3 overexpression/molecular alterations are associated with a non-T-cell inflamed tumor microenvironment. Rogaratinib, an oral pan-FGFR 1-4 inhibitor, has shown promising efficacy in a phase I study in UC patients selected based on FGFR1-3 overexpression, including patients who rapidly progressed on immunotherapy. The aim of this study is to explore the clinical safety and benefit of combining rogaratinib with atezolizumab.
Trial design
This is a multicenter, phase 1b/2 study of rogaratinib in combination with atezolizumab in patients with FGFR-positive locally advanced or metastatic UC. The primary objectives of the single-arm phase 1b portion are to determine the safety, tolerability, recommended phase-2 dose (RP2D) and pharmacokinetics of rogaratinib in combination with atezolizumab. The primary objective of the randomized phase 2 portion is to compare progression-free survival (PFS) of rogaratinib plus atezolizumab versus placebo plus atezolizumab in chemotherapy-untreated patients with FGFR-positive locally advanced or metastatic UC. Patients will be tested for FGFR1/3 mRNA expression levels in archival tumor samples (RNAscope®) and patients with FGFR-positive UC will enter into screening, regardless of the presence of FGFR mutations or translocations. Eligible patients will be treated with a starting dose of daily rogaratinib 800 mg po bid together with a fixed dose of 1200 mg atezolizumab iv on day 1 of a 21-day cycle. Following determination of the RP2D, patients will be randomized 1:1 to rogaratinib plus atezolizumab versus placebo plus atezolizumab. The primary efficacy variable is PFS based on assessment of blinded independent central review. Approximately 160 patients will be enrolled.
Clinical trial identification
NCT03473756.
Legal entity responsible for the study
Bayer AG.
Funding
Bayer AG.
Editorial Acknowledgement
Disclosure
K. Nakajima, C. Lu, H. Nogai: Employee: Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract